Vorarlberger Krankenhaus-Betriebsgesellschaft mbH — Clinical Trial Site

42 Registered trials

22 Currently recruiting

Organisation

Vorarlberger Krankenhaus-Betriebsgesellschaft mbH

Location

Feldkirch, Austria

Identifier

ORG-100021098

Address

Carl-Pedenz-Strasse 2, 6900, Austria

Departments

4101:Interne Medizin
Abteilung fuer Kinder und Jugenheilkunde
Abteilung für Dermatologie und Venerologie
Department of Internal Medicine 3 – Nephrology, Dialysis and Hypertensiology
Department of Internal Medicine II
Department of Internal Medicine III
Department of Internal Medicine III – Nephrology, Dialysis and Hypertensiology
Department of Oncology
Division of Paediatric and Adolescent Medicine
Genecology and Obstetrics
General, Visceral and Thoracic Surgery
Internal E at LKH Rankweil
Internal E department at LKH Rankweil, Valdunastrasse 16, 6830 Rankweil, Austria
Internal Medicine
Internal Medicine II
Internal Medicine II at LKH Rankweil
Internal Medicine II Oncology, Hematology, Gastroenterology, Infectiology
Internal Medicine II, Interne E
Internal Medicine II, Interne E (Hematology and Oncology)
Internal Medicine II, Oncology - Internal E
Internal Medicine III Nephrology, Dialysis and Hypertension
Interne Abteilung, Station Interne E, Onkologie
Interne E
Interne E (Hämatologie und Onkologie)
Interne E am LKH Rankweil
Interne E at LHK Rankwell
Koop. Gruppe Gyn./Int. Abteilung
Landeskrankenhaus Feldkirch
Landeskrankenhaus Feldkirch, Department of Internal Medicine E at Landeskrankenhaus Rankweil
LKH Rankweil, Department of Internal Medicine II, Interne E
Onkologie, Hämatologie
VIVIT Institute
Vorarlberg Institute for Vascular Investigation and Treatment
Vorarlberg Institute for Vascular Research (VIVIT), Specialist Hospital, Internal Medicine I

Clinical trials at this site (42)

Search interface

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 advanced or metastatic adenocarcinoma of the stomach or 5 2016-11-07
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15